UBS Group AG Buys 32,192 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)

UBS Group AG grew its stake in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGLFree Report) by 57.3% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 88,377 shares of the biopharmaceutical company’s stock after purchasing an additional 32,192 shares during the period. UBS Group AG owned about 0.45% of Madrigal Pharmaceuticals worth $20,449,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Montag A & Associates Inc. lifted its stake in Madrigal Pharmaceuticals by 223.3% in the third quarter. Montag A & Associates Inc. now owns 194 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 134 shares during the last quarter. Global Retirement Partners LLC lifted its stake in Madrigal Pharmaceuticals by 454.5% in the fourth quarter. Global Retirement Partners LLC now owns 122 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 100 shares during the last quarter. Quantbot Technologies LP purchased a new position in Madrigal Pharmaceuticals in the third quarter valued at approximately $72,000. Xponance Inc. purchased a new position in Madrigal Pharmaceuticals in the fourth quarter valued at approximately $206,000. Finally, New Harbor Financial Group LLC purchased a new position in Madrigal Pharmaceuticals in the fourth quarter valued at approximately $211,000. Hedge funds and other institutional investors own 98.50% of the company’s stock.

Madrigal Pharmaceuticals Trading Down 0.3 %

Madrigal Pharmaceuticals stock opened at $222.51 on Thursday. Madrigal Pharmaceuticals, Inc. has a fifty-two week low of $119.76 and a fifty-two week high of $299.98. The firm’s fifty day moving average price is $229.07 and its 200-day moving average price is $226.22. The company has a quick ratio of 9.39, a current ratio of 9.39 and a debt-to-equity ratio of 0.14.

Madrigal Pharmaceuticals (NASDAQ:MDGLGet Free Report) last released its quarterly earnings results on Tuesday, May 7th. The biopharmaceutical company reported ($7.38) earnings per share for the quarter, missing the consensus estimate of ($6.06) by ($1.32). During the same period in the previous year, the company earned ($4.23) EPS. As a group, analysts forecast that Madrigal Pharmaceuticals, Inc. will post -27.62 earnings per share for the current year.

Insider Transactions at Madrigal Pharmaceuticals

In related news, VP Robert E. Waltermire sold 1,036 shares of the stock in a transaction on Tuesday, May 21st. The stock was sold at an average price of $231.34, for a total value of $239,668.24. Following the transaction, the vice president now owns 5,500 shares of the company’s stock, valued at $1,272,370. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In related news, VP Robert E. Waltermire sold 1,036 shares of the stock in a transaction on Tuesday, May 21st. The stock was sold at an average price of $231.34, for a total value of $239,668.24. Following the transaction, the vice president now owns 5,500 shares of the company’s stock, valued at $1,272,370. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CMO Rebecca Taub sold 2,676 shares of the stock in a transaction on Monday, April 8th. The shares were sold at an average price of $245.99, for a total value of $658,269.24. Following the completion of the transaction, the chief marketing officer now directly owns 458,999 shares in the company, valued at approximately $112,909,164.01. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 170,021 shares of company stock valued at $36,389,547. 23.92% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several equities analysts recently commented on MDGL shares. Oppenheimer upped their price objective on Madrigal Pharmaceuticals from $320.00 to $375.00 and gave the company an “outperform” rating in a research note on Friday, March 15th. JMP Securities lowered their target price on shares of Madrigal Pharmaceuticals from $397.00 to $381.00 and set a “market outperform” rating on the stock in a report on Wednesday, May 8th. Evercore ISI boosted their target price on shares of Madrigal Pharmaceuticals from $325.00 to $405.00 and gave the company an “outperform” rating in a report on Wednesday, March 20th. B. Riley lowered their target price on shares of Madrigal Pharmaceuticals from $270.00 to $200.00 and set a “neutral” rating on the stock in a report on Friday, May 10th. Finally, Bank of America began coverage on shares of Madrigal Pharmaceuticals in a report on Monday, April 22nd. They set an “underperform” rating and a $150.00 target price on the stock. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Madrigal Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $345.09.

Get Our Latest Stock Report on MDGL

Madrigal Pharmaceuticals Company Profile

(Free Report)

Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH.

Recommended Stories

Institutional Ownership by Quarter for Madrigal Pharmaceuticals (NASDAQ:MDGL)

Receive News & Ratings for Madrigal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Madrigal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.